Schwan Cosmetics is a global market leader in the development and production of cosmetic pencils with more than 2,600 employees at nine production facilities worldwide.
For an eye-catching look and a voluminous lash line, many consumers turn to either eyelash and eyebrow serums or colored liquid liners. Schwan Cosmetics strongly believes that cosmetics should not compromise beauty or health.
The LASHBOOST Enhancing Serum Liner underlines this believe: It is a 2-in1 colored liquid eyeliner with proven efficiency for the daily eye make-up. It increases the number of eyelashes by 20%1, and 87%2 of study participants have agreed that hair loss is slowed. LASHBOOST lasts up to 15 hours smudge proof.
The texture is vegan, ophthalmologically tested and any controversial ingredients have been strictly avoided.
You can find further information under www.schwancosmetics.com
Dermatest® test procedure:
Clinical application study under dermatological control. The test product was applied during a period of four weeks by 20 subjects once a day onto the eyelid. From the clinical-dermatological point of view, no relevant skin reactions occurred in the test area; the product was tolerated excellently.
Neither intolerance reactions suggestive of irritation nor allergic reactions (contact dermatitis) were detected. Accordingly, from the dermatological viewpoint, there is no high potential for irritation and sensitisation for the tested product when used as intended.
The Dermatest seal:
When it comes to your eyes, it is all the more important for you to know which products are dermatologically tested and safe. Certificates like those from us as an independent institute help you to assess the safety of products for you. The LASHBOOST Eyeliner met the highest test requirements and therefore received the “5-star-guarantee” seal.
1Measurable results With Photoshop® based on a 12-week efficacy study; N=31; Improvement observed on 90% of participants.
2Participant self-assessment after 12 weeks of daily use of the product; as part of the claim efficacy study; N=33.